TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.

Inclusion Criteria: 1. Patients with unresectable hepatocellular carcinoma; 2. More than 18 years old; 3. Patients diagnosed with hepatocellular carcinoma by histopathology or imagings; 4. Liver function ChildPugh ≤7 points, Physical strength score ECOG-pts 0-1 points; 5. Maximum tumor diameter ≤10cm, tumor number ≤10, no vascular invasion or extrahepatic metastasis; 6. Other organs of the whole body function well; 7. Sign the informed consent; 8. Passed the review by the ethics committee. Exclusion Criteria: 1. Less than 18 or more than 70 years old; 2. Lack of autonomous decision-making ability; 3. ECOG score \>2, cachexia or multiple organ failure; 4. Metastases; The tumor was diffuse or metastasized widely and the expected survival time was less than 3 months. 5. Uncorrectable coagulation dysfunction with a history of bleeding; Organ transplant; 6. Patients with severe autoimmune diseases; Iodine contrast agent allergy; High allergic constitution; 7. The main portal vein was completely blocked by cancer embolism, with little collateral vascular formation; 8. Severe infection; AIDS, syphilis infection; 9. T cell lymphoma; 10. Patients with mental illness, severe trauma or other stress conditions; 11. Pregnant or nursing women; 12. Abnormal peripheral blood routine detection; 13. Failing to comply with the study protocol to complete the diagnosis and treatment project; Failed ethics committee review.